ISN-ACT Clinical Trial List: June 2019
ISN Academy. ISN-ACT . 06/06/19; 273552; 6175 Topic: Global Nephrology
Disclosure(s): The ISN-Advancing Clinical Trials is a new initiative of the ISN intended to leverage existing infrastructures within ISN, in order to improve global nephrology community participation in clinical trial research. As part of its activities, the ISN-ACT highlights and sometimes analyzes important recent nephrology trials from latest medical literature every month through the ISN-ACT Trial-list. Editors of the ISN-ACT Trial-List also select clinical trials of particular impact, and collaborate with the @ISNeducation social media learning team to represent these trials visually. Join the ISN-ACT To generate more high-quality clinical trials and studies in nephrology, ISN-ACT is calling on investigators and interested individuals. If you are an ISN member interested to join this great initiative, submit your application online. Use the button below (download PDF) to download this month's edition of the list.
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Discussion Forum (0)
Rate & Comment (0)
Once a month, the ISN-ACT (Advancing Clinical Trials) team collects and publishes a list of important nephrology trials from the latest medical literature. Each trial is reviewed in context and their risk of bias in seven key areas assessed.

This month, we reviewed the following trials:

- Taking DELIGHT in lowering BSL and albuminuria in type 2 diabetics with CKD
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Pollock, et al. Lancet Diabetes Endocrinol. 2019;7(6):429-441

- PCKD puzzle: Octreotide fails to slow GFR decline, but does slow kidney growth and may reduce ESKD
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
Perico, et al. PLoS Med. 2019;16(4):e1002777

- Interactive decision aid reduces uncertainty and conflict, and improves knowledge in patients choosing dialysis modality
Use of a Decision Aid for Patients Considering Peritoneal Dialysis and In-Center Hemodialysis: A Randomized Controlled Trial
Subramanian, et al. Am J Kidney Dis. 2019 Apr 3. pii: S0272-6386(19)30160-X

- Magnesium may slow coronary artery calcification in stage 3-4 CKD A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD Sakaguchi, et al. J Am Soc Nephrol. 2019;30(6):1073-1085

- Bee resin creating a buzz: Brazilian green propolis reduces proteinuria in small study
Effects of Brazilian green propolis on proteinuria and renal function in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled trial
Silveira, et al. BMC Nephrol. 2019;20(1):140

- Everolimus-CnI regime may not stack up to mycophenolate-tacrolimus in transplantation
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients
Sommerer et. al. Kidney Int. 2019 Feb 27. pii: S0085-2538(19)30193-0

- No improvement in quality of life or strength with cholecalciferol supplementation in dialysis patients
Placebo-controlled, randomized clinical trial of high-dose cholecalciferol in renal dialysis patients: effect on muscle strength and quality of life
Singer, et. al. Clin Kidney J. 2018;12(2):281-287

- Intraoperative use of saline-bicarbonate solution associated with better early graft function
Half Saline-Bicarbonate Solution as Intraoperative Fluid Replacement Therapy Leads to Less Acidosis and Better Early Renal Function During Deceased-Donor Transplant
Pourfakhr, et al. Exp Clin Transplant. 2019 Apr 17. doi: 10.6002/ect.2018.0328

- Corticosteroid reduction when switching from cyclosporine to PR tacrolimus may be possible in selected transplant recipients
Randomized, Open-Label, Phase IV, Korean Study of Kidney Transplant Patients Converting from Cyclosporine to Prolonged-Release Tacrolimus Plus Standard- or Reduced-Dose Corticosteroids
Baek, et al. Transplant Proc. 2019;51(3):749-760

- Busting B-lines: a way to better blood pressure
The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial
Loutradis, et al. Kidney Int. 2019;95(6):1505-1513

- Lavender oil may ease the pain of cannulation
The effect of diluted lavender oil inhalation on pain development during vascular access among patients undergoing haemodialysis
Taşan, et al. Complement Ther Clin Pract. 2019;35:177-182

A preview of this infographic is available below, and can be downloaded to the left.

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies